Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future.
All content for Hopkins Biotech Podcast is the property of Hopkins Biotech Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future.
James Coates: Company Growth Through Strategic Advising
Hopkins Biotech Podcast
24 minutes
3 years ago
James Coates: Company Growth Through Strategic Advising
Dr. James Coates is currently the Principal for Health & Human Performance at Decisive Point, an East coast venture capital firm that invests in and supports startups with deep tech and government use cases. James holds a Ph.D. in Cancer Drug Discovery and MSc in Radiation Biology and Oncology, both from the University of Oxford, and he conducted technical diligence for Bain Capital Life Sciences prior to joining Decisive Point. In this episode, we discuss his career path and transi...
Hopkins Biotech Podcast
Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future.
